Cocaine Rehab Cost in Pennsylvania: Contingency Management, Pricing, 2026 Reality
Cocaine rehab in Pennsylvania costs $17,000 to $50,000 for a 30-day inpatient program without insurance, or $6,500 to $19,000 out-of-pocket with PPO insurance. Unlike opioids and alcohol, cocaine use disorder has no FDA-approved medication — contingency management (CM) is the most evidence-based treatment, increasingly covered by Pennsylvania commercial insurers and PA Medicaid. Fentanyl is increasingly contaminating the PA cocaine supply, and in Philadelphia xylazine contamination adds tri-contamination risk (cocaine + fentanyl + xylazine) — a particularly dangerous pattern unique to Philadelphia. PA Medicaid covers the full continuum at $0 for 3.5 million enrollees; 47 Single County Authorities (SCAs) serve uninsured residents across all 67 counties.
Cocaine use disorder treatment in Pennsylvania in 2026 sits at an inflection point. The absence of FDA-approved MAT is a real clinical limitation, but contingency management has emerged as an evidence-based intervention with strong outcomes. PA’s 2015–2024 policy infrastructure (Medicaid expansion, COE model, SCA system, Act 106 parity, Treatment Atlas, $1.07B Opioid Settlement Fund) supports CM coverage and ASAM-aligned medical necessity. Fentanyl contamination of the cocaine supply — particularly severe in Philadelphia where xylazine compounds the risk — adds overdose danger for stimulant-only users. This guide combines PA-specific clinical reality with the PA policy stack.
The PA Cocaine Reality: No MAT, But CM Works
The clinical honesty competitors avoid: there is no FDA-approved medication for cocaine use disorder as of 2026.
What Works: Contingency Management
Contingency management (CM) is a behavioral intervention providing small tangible incentives (gift cards, vouchers, prize drawings) contingent on negative drug tests or treatment attendance. Evidence base:
- Retention rates 70%+ in some studies
- Medium-to-large effect sizes on abstinence in meta-analyses
- Strongest psychosocial evidence of any cocaine intervention
- Works by providing an alternative reward pathway
CM Availability in Pennsylvania
- Penn Medicine Center for Studies of Addiction — research-grade CM
- Temple University Center for Substance Abuse Research — research-grade CM
- Jefferson Health Addiction Medicine — CM programs
- UPMC Addiction Medicine — CM programs
- Allegheny Health Network
- Community providers — ask specifically
- SCA-contracted providers — some offer CM
- PA Medicaid Managed Care — CM coverage expanding
- Commercial insurers under Act 106 + MHPAEA — increasingly covering CM
Off-Label Pharmacotherapy at PA Academic Centers
- Topiramate — modest evidence for reducing cocaine use
- Bupropion — useful with co-occurring depression
- Modafinil — mixed evidence; studied at Penn and Temple
- Naltrexone + bupropion combination — early evidence
- Disulfiram — studied for cocaine
Penn Medicine, Temple, Jefferson, UPMC, and Allegheny Health Network offer clinical trials.
Why Pennsylvania Is Different for Cocaine Treatment
1. Philadelphia Tri-Contamination Risk (Cocaine + Fentanyl + Xylazine)
Philadelphia has among the nation’s highest xylazine rates in the fentanyl supply (90%+). When cocaine is contaminated with fentanyl in Philadelphia, it’s often also contaminated with xylazine. This tri-contamination is unique to Philadelphia and dangerous for stimulant-only users with no opioid tolerance.
2. Centers of Excellence (COE) — Integrated Care
PA’s 45+ COEs integrate stimulant treatment with primary care and behavioral health. Particularly valuable for cocaine patients with co-occurring conditions.
3. Medicaid Expansion (2015) — 3.5 Million Enrollees
Covers full cocaine continuum + CM at $0 through managed care plans.
4. Act 106 (2024) Parity Enforcement
State parity enforcement on top of federal MHPAEA. Applies to stimulant UD.
5. Single County Authority (SCA) System
47 SCAs serve all 67 PA counties. Free/sliding-scale cocaine treatment.
6. Strong PA Academic Addiction Medicine
Penn Medicine Center for Studies of Addiction, Temple Center for Substance Abuse Research — national leaders in cocaine pharmacotherapy research.
7. Prevention Point Philadelphia Harm Reduction
Nation’s oldest SSP provides fentanyl test strips — critical access point for PA cocaine users at risk from fentanyl-contaminated cocaine.
8. PA Opioid Settlement Fund Stimulant Allocation
$1.07B+ fund includes some stimulant UD allocation given rising polysubstance use.
For full Pennsylvania regulatory context, see rehab cost in Pennsylvania. For cocaine-specific clinical treatment nationally, see cocaine rehab cost.
Cocaine Rehab Cost in PA: 2026 Breakdown
| Level of Care | Duration | Without Insurance | With PPO |
|---|---|---|---|
| Medical observation / crash monitoring | 5–7 days | $1,250 – $3,850 | $500 – $2,695 |
| Inpatient residential (standard) | 30 days | $17,000 – $28,000 | $6,500 – $14,000 |
| Inpatient residential (mid-tier) | 30 days | $28,000 – $40,000 | $11,000 – $18,000 |
| Main Line / Philly luxury | 30 days | $42,000 – $80,000+ | Capped at OOP max |
| Partial hospitalization (PHP) | 4–6 weeks | $5,000 – $16,000 | Capped at OOP max |
| Intensive outpatient with CM | 8–12 weeks | $4,000 – $12,000 | Capped at OOP max |
| Standard outpatient with CM | 6–12 months | $1,500 – $6,000 | Capped at OOP max |
| Contingency management incentives | 12–24 weeks | $300 – $1,000 total | Increasingly covered |
PA Medicaid covers all of the above at $0 for eligible enrollees.
Fentanyl-Contaminated Cocaine: The PA Threat
PA Department of Health, Philadelphia DPH, Prevention Point Philadelphia drug checking, and DEA data all show rising fentanyl contamination of the PA cocaine supply. Philadelphia specifically faces tri-contamination risk: cocaine samples may contain both fentanyl and xylazine simultaneously.
Why It’s Especially Dangerous in Philadelphia
Cocaine users typically have no opioid tolerance. A fentanyl-laced bag can cause fatal respiratory depression at doses a tolerant opioid user would survive. In Philadelphia, the added xylazine contamination creates additional risks:
- Naloxone doesn’t reverse xylazine sedation (though still needed for fentanyl component)
- Multiple naloxone doses required
- Extended monitoring for xylazine respiratory/sedation effects
- Potential wound care if the user injected cocaine contaminated with xylazine
PA Harm Reduction Response
- PA DOH Project Free Naloxone — free naloxone through participating pharmacies and community orgs
- Prevention Point Philadelphia — fentanyl and xylazine test strips, naloxone, Kensington crisis response
- Philadelphia DPH Drug Checking Program — fentanyl and xylazine detection
- Public health alerts from PA DOH, Philadelphia DPH
- PA Good Samaritan Law (Act 139 of 2014) — protection for 911 callers
- Education that any cocaine in PA may contain fentanyl
Treatment Planning Implications
Cocaine patients with any history of using fentanyl-contaminated cocaine are effectively dual-substance patients. In Philadelphia, potential xylazine exposure adds another layer. PA treatment programs increasingly screen for all substances; patients often benefit from opioid MAT alongside CM and CBT for the stimulant component.
For full fentanyl mechanics in PA, see fentanyl rehab cost in Pennsylvania.
Cocaine Withdrawal and the “Crash”
Cocaine withdrawal is not medically dangerous like alcohol or benzo withdrawal — but psychologically intense.
Timeline
| Phase | Duration | Clinical Picture |
|---|---|---|
| Crash | 24–72 hours | Fatigue, depression, appetite increase, hypersomnia |
| Acute withdrawal | 1–2 weeks | Anhedonia, cravings, sleep disturbance, depression |
| Subacute | 2–10 weeks | Cravings persist, mood stabilizing |
| PAWS | Months | Episodic cravings, mood changes |
What Detox Includes in PA
- 24/7 nursing observation
- Psychiatric assessment for suicidality (crash-phase depression can be severe)
- Sleep aids (trazodone, hydroxyzine)
- Nutritional support and hydration
- Cardiac screening (cocaine can cause MI, arrhythmia, cardiomyopathy)
- Co-occurring substance management (alcohol, opioid withdrawal if polysubstance)
- Screening for fentanyl + xylazine exposure
- Warm handoff to residential or outpatient with CM
Polysubstance Treatment: The PA Reality
Most PA cocaine patients are not only cocaine patients. Common PA polysubstance patterns:
- Cocaine + alcohol — “speedball” concept; high cardiac risk
- Cocaine + fentanyl-contaminated cocaine — unintentional opioid exposure
- Cocaine + fentanyl + xylazine — Philadelphia tri-contamination
- Cocaine + opioid — classic speedball
- Cocaine + benzodiazepines
- Cocaine + methamphetamine — rising in rural PA
PA treatment programs integrate: CM for stimulants, alcohol MAT if AUD, opioid MAT if OUD detected, xylazine-specific protocols, and treatment of co-occurring psychiatric conditions. COE model is particularly well-suited.
Cocaine Treatment Length in PA
Evidence-based sequence:
- Medical observation / crash support (5–7 days)
- Residential or PHP (30–90 days)
- IOP with contingency management (8–12 weeks)
- Standard outpatient with continued CM (6–12 months)
- Recovery support and co-occurring treatment (ongoing)
NIDA recommends minimum 90 days structured care. Under Act 106, PA insurers cannot impose arbitrary day caps. CM effectiveness peaks in the first 12–24 weeks.
How Do Pennsylvanians Afford Cocaine Rehab?
1. PA Medicaid (3.5 Million Enrollees)
Full continuum + CM at $0 through managed care plans.
2. Private Commercial Insurance
Highmark BCBS, Independence Blue Cross, UPMC Health Plan, Geisinger, Aetna, UHC. Capped at $7,000–$9,500 OOP max.
3. Single County Authorities (SCAs)
47 SCAs, 67 counties. Call 1-800-662-4357.
4. Gaudenzia Nonprofit (30+ PA locations)
5. Pennie (PA Marketplace)
Subsidized premiums.
6. PA Opioid Settlement Fund Stimulant Programs
Some allocation given polysubstance reality.
7. Centers of Excellence (COE)
Integrated care.
8. Faith-Based and Sliding-Scale
Salvation Army ARCs, Teen Challenge PA, 45+ FQHCs.
9. Prevention Point Philadelphia
Harm reduction + MAT/treatment referral for cocaine users.
Choosing a PA Cocaine Rehab
Verification questions before admission:
- Is the facility DDAP-licensed? Verify via Treatment Atlas
- Is the facility accredited (Joint Commission, CARF, COA)?
- Do you offer contingency management?
- How do you handle polysubstance use (especially fentanyl-contaminated cocaine)?
- Do you screen for fentanyl/xylazine exposure?
- Is the facility in-network for my plan?
- Are you a Center of Excellence (COE)?
- Are you an SCA-contracted provider (if uninsured)?
- What’s the outpatient / IOP continuation plan?
- What’s my deductible and OOP max, and what’s met year-to-date?
Pennsylvania Cocaine Resources
State Resources
- PA Get Help Now Helpline: 1-800-662-4357 (24/7)
- PA DDAP: pa.gov/agencies/ddap
- Philadelphia DBHIDS: 215-685-6440
- SAMHSA National Helpline: 1-800-662-4357
- 988 Suicide & Crisis Lifeline: 988
Harm Reduction
- Prevention Point Philadelphia — fentanyl/xylazine test strips + naloxone
- PA DOH Project Free Naloxone — free naloxone
- Philadelphia DPH Drug Checking Program — fentanyl/xylazine detection
Major Counties
- Philadelphia: 215-685-6440 (DBHIDS)
- Allegheny (Pittsburgh): 412-350-4457
- Montgomery / Bucks / Chester / Delaware: 211
- Lehigh Valley: 211
- Dauphin (Harrisburg): 211
Support Groups
- Cocaine Anonymous Pennsylvania — meetings statewide
- AA Pennsylvania — for co-occurring alcohol use
- SMART Recovery Pennsylvania — science-based
- PRO-ACT — PA Recovery Organizations statewide peer support
Final Thoughts
Pennsylvania cocaine treatment in 2026 faces the clinical limitation of no FDA-approved MAT, balanced by increasingly available contingency management and PA’s strong integrated care infrastructure (COE model, SCA system, Medicaid expansion). Fentanyl contamination of the cocaine supply — with Philadelphia’s additional xylazine tri-contamination — adds lethal overdose risk for stimulant-only users.
Five steps:
- Check PA Medicaid eligibility — 3.5M qualify for $0 coverage
- Ask about contingency management at the admitting facility
- Screen for polysubstance use — especially fentanyl-contaminated cocaine
- Carry naloxone + use fentanyl test strips given contamination risk
- If uninsured: Call 1-800-662-4357 for SCA referral
For broader context, see rehab cost in Pennsylvania, cocaine rehab cost, alcohol rehab cost in Pennsylvania (polysubstance context), fentanyl rehab cost in Pennsylvania, and medical detox cost.
Sources
- Pennsylvania Department of Health. “Drug Overdose Data.” 2023.
- Philadelphia Department of Public Health. “Drug Supply Surveillance.” 2023–2024.
- Prevention Point Philadelphia. “Drug Checking Program.” 2024.
- Pennsylvania DDAP. “Centers of Excellence and Stimulant UD.” 2024.
- PA Opioid Misuse and Addiction Abatement Trust. 2024.
- Drug Enforcement Administration. “National Drug Threat Assessment.” 2024.
- National Institute on Drug Abuse. “Cocaine Research Report.” 2024.
- Higgins ST, et al. “Contingency Management for Stimulant Use Disorder: A Systematic Review.” Addiction. 2024.
- American Society of Addiction Medicine. “Clinical Guidance on Stimulant Use Disorder.” 2023.
- Pennsylvania Act 106 (2024). “Mental Health and Substance Use Disorder Parity.”
- Pennsylvania Act 139 of 2014. “Good Samaritan Law.”
- Penn Medicine Center for Studies of Addiction. “Cocaine Pharmacotherapy Research.” 2024.
- U.S. Department of Labor. “Mental Health Parity and Addiction Equity Act Final Rule (September 2024).”
- SAMHSA Behavioral Health Treatment Services Locator. 2025. https://findtreatment.samhsa.gov/
Cocaine Treatment in Pennsylvania — Is Your Plan Enough?
Even with insurance, many people discover their plan doesn't cover residential treatment at the level they need. A broker who specializes in behavioral health coverage can review your situation and find a plan that works.
Call 1-866-454-9577Free Consultation · No Obligation
Prodest Insurance Group is a licensed, independent health insurance brokerage. Calling the number above connects you with a licensed insurance agent, not a treatment facility. Insurance placement is a separate service from treatment referral.
Frequently Asked Questions
How much does cocaine rehab cost in Pennsylvania?
Cocaine rehab in Pennsylvania costs $17,000–$50,000 for 30 days of inpatient treatment without insurance, or $6,500–$19,000 out-of-pocket with PPO insurance (capped at the 2026 OOP max of $7,000–$9,500). Detox typically runs 5–7 days and is shorter than for alcohol, opioids, or benzodiazepines because cocaine withdrawal is primarily psychological rather than medically dangerous. Contingency management (CM), the most evidence-based treatment for cocaine use disorder, is offered by PA commercial insurers and PA Medicaid at eligible providers. Ongoing outpatient or IOP runs $1,500–$5,000/month insured, or $0 with PA Medicaid. Philadelphia Main Line luxury programs run $42,000–$80,000+; Pittsburgh metro and mid-tier $25,000–$40,000; Central and rural PA $17,000–$28,000.
Is there FDA-approved medication for cocaine addiction?
No. As of 2026, there is no FDA-approved medication-assisted treatment specifically for cocaine use disorder. This distinguishes cocaine treatment from opioid and alcohol treatment, where multiple MAT options exist. What Pennsylvania clinicians use instead: (1) contingency management (CM) as the gold-standard evidence-based intervention — patients earn small rewards for negative drug tests with retention rates reaching 70%+ in some studies; (2) cognitive behavioral therapy (CBT) and motivational interviewing; (3) off-label pharmacotherapy being actively studied at Pennsylvania academic centers (Penn Medicine, Temple Health, Jefferson, UPMC, Allegheny Health Network) — topiramate, bupropion, modafinil, naltrexone + bupropion combination; (4) treatment of co-occurring depression, anxiety, or ADHD. PA Centers of Excellence (COE) provide integrated care that's particularly valuable for cocaine patients with co-occurring conditions.
Is cocaine contaminated with fentanyl in Pennsylvania?
Yes, and the contamination rate is particularly dangerous in Philadelphia. Philadelphia Department of Public Health, Prevention Point Philadelphia drug checking, and DEA surveillance data show rising fentanyl contamination of the PA cocaine supply. In Philadelphia specifically, the picture is even more complex: cocaine samples may contain both fentanyl AND xylazine (since Philadelphia has 90%+ xylazine in fentanyl samples), creating tri-contamination risk. Fentanyl-contaminated cocaine is especially dangerous because cocaine users typically have no opioid tolerance — a fentanyl-laced bag can cause fatal respiratory depression at doses a tolerant opioid user would survive. PA overdose data indicate fentanyl is increasingly appearing in stimulant-only users. Harm reduction response: (1) PA DOH Naloxone Distribution provides free naloxone; (2) fentanyl test strip distribution through Prevention Point Philadelphia and other authorized SSPs; (3) Philadelphia DPH drug checking program; (4) public health alerts. Carrying naloxone and using fentanyl test strips is evidence-based harm reduction for PA cocaine users.
Does Pennsylvania Medicaid cover cocaine rehab?
Yes, comprehensively. PA Medicaid (Medical Assistance) covers the full cocaine use disorder treatment continuum at $0 cost for 3.5 million enrollees through managed care plans (AmeriHealth Caritas, Highmark Wholecare, UPMC for You, Keystone First, Geisinger Health Plan): medical observation/crash support (5–7 days), inpatient residential treatment, PHP, IOP, standard outpatient, and evidence-based psychotherapies (CBT, CM, MI). PA Medicaid coverage of contingency management for stimulant UD is expanding. PA's Centers of Excellence (COE) integrate stimulant treatment with primary care, behavioral health, and case management — particularly valuable for cocaine patients with co-occurring conditions. For the uninsured, 47 Single County Authorities (SCAs) provide free or sliding-scale cocaine treatment across all 67 PA counties. Apply for PA Medicaid at [compass.state.pa.us](https://www.compass.state.pa.us/) or 1-866-550-4355.
What is contingency management and does it work for cocaine?
Contingency management (CM) is an evidence-based behavioral treatment that provides small tangible incentives (gift cards, vouchers, prize drawings) contingent on negative drug tests or attendance at treatment sessions. For stimulant use disorder specifically, CM has the strongest evidence base of any psychosocial intervention — retention rates reach 70%+ in some studies, with meta-analyses showing medium-to-large effect sizes on abstinence. The mechanism: substance use hijacks the brain's reward system; CM provides an alternative reward pathway that reinforces abstinence. Pennsylvania academic medical centers (Penn Medicine, Temple Health, Jefferson, UPMC, Allegheny Health Network, Einstein) and many community providers offer CM. PA Medicaid covers CM at eligible providers. Under Act 106 + the 2024 federal MHPAEA final rule, PA commercial insurers face increasing pressure to cover CM. Ask facilities and outpatient providers whether CM is offered.
How is Pennsylvania handling polysubstance use involving cocaine?
Pennsylvania treatment programs have integrated polysubstance approaches given rising fentanyl contamination of the cocaine supply — particularly severe in Philadelphia due to xylazine presence. Common PA polysubstance patterns: (1) cocaine + alcohol — traditional 'speedball'; high cardiac risk; (2) cocaine + fentanyl-contaminated cocaine — unintentional opioid exposure in stimulant-only users; (3) cocaine + fentanyl + xylazine (Philadelphia tri-contamination) — most dangerous pattern in the nation; (4) cocaine + opioid — classic speedball; (5) cocaine + benzodiazepines. PA treatment programs integrate: CM for stimulants, alcohol MAT if AUD (naltrexone/Vivitrol, acamprosate), opioid MAT if OUD detected (buprenorphine, Brixadi, Vivitrol), xylazine-specific protocols when contamination is documented, and treatment of co-occurring psychiatric conditions. PA's Centers of Excellence (COE) model is particularly well-suited to complex polysubstance cases.
How do Pennsylvanians without insurance access cocaine treatment?
Pennsylvania has multiple pathways for uninsured cocaine treatment: (1) Single County Authorities (SCAs) — 47 SCAs serving all 67 PA counties provide free or sliding-scale cocaine treatment including CM; call PA Get Help Now Helpline at 1-800-662-4357 for local referral; (2) Gaudenzia nonprofit network — PA's largest nonprofit treatment provider with 30+ locations statewide; (3) 45+ Federally Qualified Health Centers (FQHCs) offering stimulant UD treatment on sliding fee scale; (4) Pennie (PA's state-based marketplace) offers subsidized plans with premiums $30–$450/month; (5) PA Opioid Settlement Fund–supported programs (some stimulant allocation); (6) faith-based residential (Salvation Army ARCs in Philadelphia, Pittsburgh, Harrisburg, Erie; Teen Challenge PA); (7) Prevention Point Philadelphia provides harm reduction and connection to treatment. SCA is typically the primary entry point for publicly-funded access.
How long does cocaine rehab take in Pennsylvania?
Cocaine treatment duration varies based on severity. Typical evidence-based Pennsylvania sequence: 5–7 day medical observation/crash support (cocaine withdrawal is not medically dangerous but intense depression and cravings require monitoring), 30–90 day residential or PHP, 8–12 week IOP with contingency management, and 6–12 months standard outpatient with continued CM. NIDA recommends minimum 90 days of structured care. Under Act 106 + federal MHPAEA, PA commercial insurers cannot impose arbitrary day caps. PA Medicaid covers the full continuum at $0 for eligible enrollees. CM effectiveness peaks in the first 12–24 weeks of active intervention; most patients benefit from extended outpatient and recovery support.
What off-label medications are being studied for cocaine at PA academic centers?
Several medications are being actively studied at Pennsylvania academic centers for cocaine use disorder, though none are FDA-approved for this indication as of 2026. Agents with some evidence: (1) topiramate — anticonvulsant, modest evidence for reducing cocaine use; (2) bupropion — antidepressant, useful especially for depression + cocaine co-occurrence; (3) modafinil — mixed evidence; studied at Penn and Temple; (4) naltrexone + bupropion combination — early evidence; (5) disulfiram — dopamine metabolism effects; studied for cocaine. Pennsylvania academic programs (Penn Medicine Center for Studies of Addiction, Temple University Center for Substance Abuse Research, Jefferson Addiction Medicine, UPMC Addiction Medicine, Allegheny Health Network) offer clinical trials for stimulant use disorder which can provide free access to experimental medications with full monitoring. Ask addiction medicine clinicians about trial availability.